VA gets green light to research psychedelics for veteran PTSD

What it does

This bill requires the VA to establish at least five centers of excellence across the country to research and deliver innovative therapies—including MDMA, psilocybin, ketamine, and ibogaine—for treating veteran conditions like PTSD, depression, chronic pain, and substance use disorder. The centers must be affiliated with medical schools, conduct peer-reviewed research, and report annually to Congress on their findings and recommendations.

Why we flagged it

The bill's core mechanism is establishing VA research and clinical centers for psychedelic-assisted therapies targeting veteran mental health and chronic conditions. It is a public-health expansion, not a market-driven or narrow-beneficiary measure.

What the text implies

• The bill grants the Under Secretary broad discretion to add 'such other conditions' and 'such other therapies' beyond the named list, potentially expanding scope without future congressional approval.
• No explicit requirement that therapies be FDA-approved; centers may operate under research protocols, creating a gray zone between clinical care and experimental medicine.
• Annual reporting requirement creates public accountability but does not mandate specific outcome metrics or efficacy thresholds for continuation.
• Peer review panel is exempt from the Federal Advisory Committee Act (FACA), reducing transparency in how proposals are evaluated and selected.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Veterans with PTSD, depression, chronic pain, and substance use disorders gain access to emerging evidence-based therapies that conventional treatments have failed to address. The bill mandates rigorous peer review, academic affiliation, and annual reporting, ensuring quality control and transparency in a high-stakes clinical domain.

Who stands to gain

• VA medical facilities (infrastructure and staffing funding)
• Academic medical centers and schools of psychiatry/social work (affiliated partnerships)
• Researchers and clinicians specializing in psychedelic-assisted therapy

Named in the bill

Department of Veterans Affairs, Secretary of Veterans Affairs, Under Secretary for Health, House Committee on Veterans' Affairs, Senate Committee on Veterans' Affairs, Accredited medical schools, Schools of psychiatry, Schools of social work

Where it stands

28 cosponsors: 14 Democrats, 14 Republicans.

• Apr 3, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 3, 2025 — Referred to House Committee on Veterans' Affairs · Congress.gov: “Referred to the House Committee on Veterans' Affairs”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $560,451 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

J. Correa, the sponsor, reported $706,279 in PAC receipts in the 2026 cycle.

• Disabled American Veterans — $310,451 on 2 filings
• Iraq and Afghanistan Veterans of America Inc — $120,000 on 1 filing
• Brainfutures — $80,000 on 2 filings
• Wounded Warrior Project — $30,000 on 1 filing
• Clearmind Medicine, Inc — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.